乳酸乳杆菌对溃疡性结肠炎患者辅助治疗作用及相关机制研究  

Research on adjunctive therapeutic effects and related mechanisms of Lactobacillus plantarum in ulcerative colitis patients

作　　者：梁涛[1] 

机构地区：[1]郑州大学第一附属医院药剂科,河南郑州450052

出　　处：《中国医院药学杂志》2015年第11期1018-1022,共5页Chinese Journal of Hospital Pharmacy

基　　金：河南省科技厅重点科技攻关计划项目(编号:123102310098)

摘　　要：目的:观察乳酸乳杆菌对溃疡性结肠炎的辅助治疗效果及相关机制。方法:研究对象为121名中度以上的溃疡性结肠炎患者,随机分为对照组和观察组,对照组是常规治疗;而观察组是在常规治疗的基础上,服用乳酸菌胶囊(主要含短乳酸乳杆菌),每天3次,服药时间为1年。观察试验开始和治疗1年后2组患者的结肠镜黏膜分数、灌洗液中髓过氧化物酶的含量,同时检测2组患者治疗前后粪便中的细菌数。结果:在经过1年治疗后,通过结肠镜检验,发现观察组溃疡性结肠炎患者的临床状况有明显改善,同时观察组患者中MPO(myeloperoxidase)、粪便中的肠杆菌数量和p H值均显著降低。结论:使用活性乳酸乳杆菌能明显改善溃疡性结肠炎患者的临床状况,可以作为溃疡性结肠炎患者的长期辅助治疗措施。OBJECTIVE To observe effects of Lactobacillus lactis on colitis gravis treatment. METHODS A total of 121 moderate or severe colitis gravis patients were randomly divided into two groups, based on conventional therapy, test group was additionally treated with Laetobacillus lactis capsules （mainly containing Lactobacillus lactis）, three times a day, for one year in total. Patients in the other group had not used probiotics or similar drugs （control）. at the start of study and the end of year, content of MPO （myeloperoxidase） was compared in two groups of patients with colon mosa fraction and lavage as dis- ease activity index. Bacterial counts in feces at start and end of this study were also examined. RESULTS After treatment for one year, clinical status of colitis gravis patients were assessed by enteroscope, and the results showed significant improve- ment. Furthermore, amount of myeloperoxidase in lavage also decreased in these patients after Lactobacillus lactis treatment. Lactobacillus lactis significantly reduced fecal counts of enteric bacilli and pH values. CONCLUSION Conclusion Lactobacillus lactis can significantly improve clinical conditions of colitis gravis patients, and can be used as important long term therapy for colitis gravis patients.

关 键 词：乳酸乳杆菌 髓过氧化物酶 溃疡性结肠炎 

分 类 号：R969[医药卫生—药理学]